Update
$Mesoblast(MESO.US$ Mesoblast (MESO) has released an update. Mesoblast Limited has resubmitted a Biologics License Application (BLA) to the FDA for Ryoncil®, aiming to treat children with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD). The resubmission, buoyed by promising Phase 3 study results demonstrating significant survival benefits, could meet an urgent need for effective treatment in this patient group, as current survival outcomes are poor and no FDA-approved treatments exist for children under 12 with SR-aGVHD. With Fast Track and Priority Review designations, Ryoncil® could be approved within a 2 to 6-month review period upon acceptance of the BLA.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
101674396 : Hold or sell?
Trytosaveabit OP 101674396 : Sorry I don’t give buy/sell advice! There’s no way for me to know others risk tolerance or the type of trade they are doing! I will say that I am still bullish on this! NFA JMO! GL